Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for the advanced wound care and surgical and sports medicine markets in the United States. Its advanced wound care portfolio includes products like Affinity and Novachor, which are amnion and chorion placental allografts used as protective barriers and extracellular matrix scaffolds. The company also offers Apligraf, a bioengineered bi-layered skin substitute for venous leg ulcers and diabetic foot ulcers, and Dermagraft, a dermal substitute for diabetic foot ulcers. Other products include NuShield, PuraPly Antimicrobial, PuraPly SX, CYGNUS Dual, VIA Matrix, SimpliMax, PuraPly MZ, PuraForce, FortiShield, and TransCyte, each serving specific wound care or surgical needs. Additionally, Organogenesis is developing ReNu, a cryopreserved suspension currently in Phase 3 trials for management of certain conditions.

Organogenesis Holdings Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ORGO. The trading currency for its shares is the US Dollar (USD). As a US-based company, its stock is traded in the United States, and investors typically transact in USD. The NasdaqCM is a US stock exchange that lists smaller-capitalization companies, providing liquidity and visibility for Organogenesis within the American equity markets.

Organogenesis Holdings Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification reflects its focus on developing and commercializing regenerative medicine products, which are specialized therapeutic solutions for wound care and surgical applications. As a specialty drug manufacturer, the company produces advanced biologics and medical devices that are distinct from traditional pharmaceuticals, targeting specific medical needs such as chronic wounds and surgical tissue repair.

Organogenesis Holdings Inc. is headquartered in the United States and primarily serves the American market. The company's products are marketed for advanced wound care, surgical, and sports medicine applications across the country. While its operations are focused on the US, its regenerative medicine products, such as Apligraf and Dermagraft, are used in clinical settings nationwide to treat conditions like venous leg ulcers, diabetic foot ulcers, and surgical wounds. The company's geographic concentration on the US market is reflected in its regional classification as 'us'.

Organogenesis Holdings Inc. has a diverse portfolio of regenerative medicine products. Key advanced wound care products include Apligraf, a bioengineered bi-layered skin substitute for venous leg ulcers and diabetic foot ulcers, and Dermagraft, a dermal substitute for diabetic foot ulcers. The company also offers placental allografts like Affinity and Novachor, as well as antimicrobial barriers such as PuraPly AM and PuraPly SX for surgical wound management. Other products include NuShield, CYGNUS Dual, VIA Matrix, SimpliMax, PuraPly MZ, PuraForce (a porcine collagen surgical matrix), FortiShield (a biosynthetic wound matrix), and TransCyte (a bioengineered tissue scaffold for burns). Additionally, ReNu, a cryopreserved suspension, is in Phase 3 trials for management of certain conditions.